Show simple item record

dc.contributor.authorSaylor, Philip J
dc.contributor.authorKeating, Nancy Lynn
dc.contributor.authorSmith, Matthew Raymond
dc.date.accessioned2011-06-13T14:59:46Z
dc.date.issued2009
dc.identifier.citationSaylor, Philip J., Nancy L. Keating, and Matthew R. Smith. 2009. Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy. Journal of General Internal Medicine 24(Suppl 2): 389-394.en_US
dc.identifier.issn0884-8734en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:4910920
dc.description.abstractBACKGROUND: More than one-third of the estimated 2 million prostate cancer survivors in the United States receive androgen deprivation therapy (ADT). This population of mostly older men is medically vulnerable to a variety of treatment-associated adverse effects. MEASUREMENTS AND RESULTS: Androgen-deprivation therapy (ADT) causes loss of libido, vasomotor flushing, anemia, and fatigue. More recently, ADT has been shown to accelerate bone loss, increase fat mass, increase cholesterol and triglycerides, and decrease insulin sensitivity. Consistent with these adverse metabolic effects, ADT has also recently been associated with greater risks for fractures, diabetes and cardiovascular disease.CONCLUSION: Primary care clinicians and patients should be aware of the potential benefits and harms of ADT. Screening and intervention to prevent treatment-related morbidity should be incorporated into the routine care of prostate cancer survivors. Evidence-based guidelines to prevent fractures, diabetes, and cardiovascular disease in prostate cancer survivors represent an important unmet need. We recommend the adapted use of established practice guidelines designed for the general population.en_US
dc.language.isoen_USen_US
dc.publisherSpringer-Verlagen_US
dc.relation.isversionofdoi:10.1007/s11606-009-0968-yen_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763167/pdf/en_US
dash.licenseLAA
dc.subjectprostate canceren_US
dc.subjectsurvivorshipen_US
dc.subjectGnRH agonistsen_US
dc.subjectosteoporosisen_US
dc.subjectbisphosphonatesen_US
dc.subjectdiabetesen_US
dc.subjectobesityen_US
dc.subjectcardiovascular diseaseen_US
dc.titleProstate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapyen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalJournal of General Internal Medicineen_US
dash.depositing.authorKeating, Nancy Lynn
dc.date.available2011-06-13T14:59:46Z
dash.affiliation.otherHMS^Medicine-Brigham and Women's Hospitalen_US
dash.affiliation.otherHMS^Health Care Policyen_US
dc.identifier.doi10.1007/s11606-009-0968-y*
dash.contributor.affiliatedSaylor, Philip
dash.contributor.affiliatedSmith, Matthew
dash.contributor.affiliatedKeating, Nancy


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record